Verge

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Verge Genomics and Eli Lilly (NYSE: LLY) have <a href="https://www.globenewswire.com/news-release/2024/11/20/2984206/0/en/Verge-Genomics-Announces-Milestones-in-Collaboration-with-Lilly-to-Discover-and-Develop-Novel-Treatments-for-ALS.html" target="_blank" aria-label="announced (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">announced</a> significant progress in their joint efforts to develop novel treatments for amyotrophic lateral sclerosis (ALS), a debilitating neurodegenerative disease. Since the collaboration began in July 2021, the partnership has utilized Verge Genomics’ artificial intelligence-driven CONVERGE platform to identify two promising drug targets.</p>
<p>This advancement marks a crucial step forward in addressing the unmet needs of ALS patients. Verge Genomics, known for its expertise in leveraging AI for drug discovery, is working alongside Eli Lilly, a major player in the pharmaceutical industry with a strong focus on neurodegeneration and genetic medicine, to bring new hope to those affected by ALS.</p>
<h3 id="harnessing-ai-for-breakthroughs-in-als-research">Harnessing AI for Breakthroughs in ALS Research</h3>
<p>The collaboration between Verge Genomics and Eli Lilly is heavily reliant on the innovative use of artificial intelligence through Verge’s proprietary CONVERGE platform. This technology has demonstrated a remarkable 83% success rate in validating prioritized drug targets in relevant models.</p>
<p>By employing AI, the partnership aims to make accurate predictions and identify meaningful targets for drug development, thereby accelerating the discovery of new treatments for ALS. This approach not only enhances the precision of drug target identification but also significantly reduces the time and cost associated with traditional drug discovery processes. The use of AI in this collaboration underscores the growing importance of technology in transforming medical research and development.</p>
<p>Eli Lilly’s commitment to developing new ALS treatments through this collaboration is underscored by its substantial financial investment, with the total deal valued at up to $694 million. This investment highlights Lilly’s strategic focus on leveraging advanced AI technology to enhance its drug discovery and development capabilities.</p>
<p>Success in this collaboration could lead to the introduction of new, effective treatments for ALS, addressing a critical need in the medical field. For Lilly, the potential breakthroughs achieved through this partnership could reinforce its position as a leader in neurodegenerative and genetic medicine, while also providing substantial returns on its investment.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="lly-stock-brief">LLY Stock Brief</h3>
<p>Eli Lilly’s stock (LLY) has experienced notable price movement amid the ongoing developments in its collaboration with Verge Genomics. As of November 20, 2024, the stock opened at $735.785 and reached a current price of $744.5 at the time of writing (11:00 AM EST), reflecting a rebound from recent lows.</p>
<p>The stock’s day low was $735.46, while the day high peaked at $752.9925. Over the past year, LLY has seen a 52-week low of $561.65 and a high of $972.53, indicating significant volatility. Despite recent fluctuations, the stock has shown resilience, with analysts recommending a “Buy” rating and setting a target mean price of $992.18. The recent price trend suggests a decline from late October highs, with volatility persisting into early November before the stock began to recover.</p>
<p>Eli Lilly boasts a market capitalization of $706.77 billion, underscoring its stature as a major player in the pharmaceutical industry. The company offers a <a href="https://tokenist.com/investing/what-is-dividend-investing/" rel="noopener noreferrer nofollow" class="deco-link">dividend rate</a> of $5.2 with a yield of 0.71%, appealing to income-focused investors. Key financial metrics include a <a href="https://tokenist.com/investing/p-e-ratio/" class="deco-link" rel="noopener noreferrer nofollow">trailing P/E ratio</a> of 80.31 and a forward P/E ratio of 32.94, reflecting investor expectations of future earnings growth.</p>
<p>The <a href="https://tokenist.com/investing/what-is-beta-in-stocks/" rel="noopener noreferrer nofollow" class="deco-link">stock’s beta</a> of 0.43 suggests lower volatility compared to the broader market. While the debt to equity ratio stands at 218.08, indicating significant leverage, the company’s strong revenue of $40.86 billion provides a solid financial foundation. With a recommendation mean of 1.71, market analysts remain optimistic about LLY’s growth prospects, driven by its innovative collaborations and strategic investments in cutting-edge medical research.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/lly-stock-rebounds-amid-ai-driven-als-research-breakthroughs/">LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs

Table of Contents

Tokenist

Other articles published on Nov 20, 2024

Blockchain Company Fnality Looking for a New CEO

Stellar Follows XRP’s Downward Trajectory As It Declines 10% Amidst High Selling Pressure

Bitcoin Crosses $94,000, Sets New All-Time High As Spot ETFs Go Live

Ethereum Foundation (EF) Releases 2024 Annual Report: A Look at its Financial Growth

House of reps orders N500bn recapitalization for Discos following prepaid meter palaver

Can Bitcoin Surpass Gold in Value?

Join our free newsletter for daily crypto updates!